Gene

ROS1

ROS proto-oncogene 1, receptor tyrosine kinase

Explore in graph →CI-GENE-00027341HGNC:10261 ENSG00000047936 NCBI 6098 CIViC Cancer geneApproved

Curated evidence

Clinical evidence (62)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–50 of 62 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
ROS1 Fusion1
Ceritinib	Lung Adenocarcinoma	Predictive	C	Supports Sensitivity Response	1	accepted	EID1248 Case report of a 77-year old male patient with lung adenocarcinoma (T2aN1M0, stage IIA) without EGFR, KRAS, or BRAF mutations, and no ALK gene rearrangement. CD72-ROS1 was identified in sequencing aft…

Cohorts

Alteration frequency by cohort (187)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved187 cohort rows (showing 50, sorted by frequency) · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Basal Cell Carcinoma (UNIGE, Nat Genet 2016) bcc_unige_2016	Skin Basal Cell Carcinoma	Ssm	144

Literature

Linked publications (20)

25 per page, newest first.

pubmedPublishedShowing 1–20 of 20 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001.
· Ann Oncol · 2019 · PMID 30980071 · validated civic_curation pubmed
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.
· Lancet Oncol · 2020 · PMID 31838015 · validated civic_curation pubmed
Crizotinib in ROS1-rearranged non-small-cell lung cancer.
· N Engl J Med · 2014 · PMID 25264305 · validated civic_curation pubmed
Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung Cancer.
· J Clin Oncol · 2018 · PMID 29596029 · validated civic_curation

ROS1 D2033N3
Cabozantinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	C	Supports Sensitivity Response	3	submitted	EID7691 A patient with ROS1 fusion-positive NSCLC was treated with crizotinib for 26 months led to response (-64%). After tumor progression, a rebiopsy sample was obtained and revealed ROS1 D2033N mutation. S… (full text at CIViC) PMID 26673800 · Drilon et al., 2016 · Open in CIViC	civic
Crizotinib	Malignant Lung Neoplasm	Predictive	C	Supports Resistance	3	submitted	EID7685 In a retrospective study, authors identified 16 ROS1 fusion-positive lung cancer patients who underwent a total of 17 repeat biopsies following disease progression on crizotinib ROS1 resistance mutat… (full text at CIViC) PMID 29333528 · Gainor et al., 2017 · Open in CIViC	civic
〃	Lung Adenocarcinoma	Predictive	C	Supports Resistance	—	submitted	EID4770 In a metastatic lung adenocarcinoma patient with a CD74-ROS1 gene fusion (a known sensitizing alteration to crizotinib) and a D2033N mutation in the ROS1 portion of the CD74-ROS1 gene fusion, D2033N w… (full text at CIViC) PMID 26673800 · Drilon et al., 2016 · Open in CIViC	civic

ROS1 G2032R6
Crizotinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Resistance	4	submitted	EID7684 In a retrospective study, authors identified 16 ROS1 fusion-positive lung cancer patients who underwent a total of 17 repeat biopsies following disease progression on crizotinib ROS1 resistance mutat… (full text at CIViC) PMID 29333528 · Gainor et al., 2017 · Open in CIViC	civic
〃	Lung Adenocarcinoma	Predictive	C	Supports Resistance	1	accepted	EID2934 Resistance to crizotinib developed in a patient with metastatic lung adenocarcinoma harboring a CD74-ROS1 rearrangement who had initially shown a dramatic response to treatment. A biopsy of a resistan… (full text at CIViC) PMID 23724914 · Awad et al., 2013 · Open in CIViC	civic
〃	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	C	Supports Resistance	—	submitted	EID4614 In a phase 1 study (NCT00585195), a stage IIIA pulmonary adenocarcinoma patient with acquired crizotinib resistance harbored a CD74-ROS1 gene rearrangement (a known sensitizing alteration to crizotini… (full text at CIViC) PMID 25688157 · Song et al., 2015 · Open in CIViC	civic
〃	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	D	Supports Resistance	—	submitted	EID4615 In an in vitro study, a Ba/F3 cell line expressing CD74-ROS1 fusion (a known sensitizing alteration to crizotinib) and a ROS1 G2032R co-mutation demonstrated resistance to crizotinib treatment (1,192 … (full text at CIViC) PMID 26372962 · Davare et al., 2015 · Open in CIViC	civic
〃	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	D	Supports Resistance	—	submitted	EID4616 In an in vitro study, a Ba/F3 cell line expressing a G2032R mutation in the ROS1 portion of the EZR-ROS1 fusion protein was associated with resistance to crizotinib treatment (IC50: 1287 nM), as comp… (full text at CIViC) PMID 27401242 · Facchinetti et al., 2016 · Open in CIViC	civic
Repotrectinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	C	Supports Sensitivity Response	3	submitted	EID7687 A patient with ROS1 fusion-positive NSCLC was treated with crizotinib. After tumor progression, a repeat biopsy revealed ROS1 G2032R mutation. The patient subsequently enrolled in the phase I repotrec… (full text at CIViC) PMID 30093503 · Drilon et al., 2018 · Open in CIViC	civic

ROS1 G2032R + ROS1 Fusion3
Lorlatinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	D	Supports Sensitivity Response	3	accepted	EID1251 Preclinical study of PF-06463922 in NSCLC in-vitro, in-vivo and in enzyme assays. PF-06463922 showed inhibition of kinase activity, cell viability and tumor growth in wild-type, G2032R and L2026M muta… (full text at CIViC) PMID 25733882 · Zou et al., 2015 · Open in CIViC	civic
Repotrectinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	3	submitted	EID12022 In a phase 1-2 trial (NCT03093116), the ROS1/ALK/NTRK inhibitor repotrectinib demonstrated efficacy in NSCLC with ROS1 fusions. In the 56 patients who had previously received one ROS1 tyrosine kinase… (full text at CIViC) PMID 38197815 · Drilon et al., 2024 · Open in CIViC	civic
Taletrectinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	2	submitted	EID12236 The TRUST-I study (NCT04395677) was a phase II, multicenter, single-arm, open-label trial conducted in China to evaluate taletrectinib for ROS1 fusion-positive, locally advanced, or metastatic non-sma… (full text at CIViC) PMID 38822758 · Li et al., 2024 · Open in CIViC	civic

ROS1 S1986F2
Crizotinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	C	Supports Resistance	3	submitted	EID7686 In a retrospective study, authors identified 16 ROS1 fusion-positive lung cancer patients who underwent a total of 17 repeat biopsies following disease progression on crizotinib ROS1 resistance mutat… (full text at CIViC) PMID 29333528 · Gainor et al., 2017 · Open in CIViC	civic
〃	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	D	Supports Resistance	—	submitted	EID4807 In an in vitro study, a Ba/F3 cell line expressing S1986F mutation in the ROS1 portion of the EZR-ROS1 fusion protein was associated with resistance to crizotinib treatment (IC50: 116 nM), as compared… (full text at CIViC) PMID 27401242 · Facchinetti et al., 2016 · Open in CIViC	civic

ROS1 Fusion4
Entrectinib	Melanoma	Predictive	C	Supports Sensitivity Response	4	accepted	EID12140 Two phase I studies included 119 patients with advanced or metastatic solid tumors, which included 28 patients with ROS1 rearrangements (n=28) where the overall safety and antitumor activity of entrec… (full text at CIViC) PMID 28183697 · Drilon et al., 2017 · Open in CIViC	civic
〃	Diffuse Midline Glioma, H3 K27-Altered	Predictive	C	Supports Sensitivity Response	3	accepted	EID11849 In a phase 1/2 trial of entrectinib in pediatric patients, tumors with fusions in NTRK, ROS1, or ALK had an overall response (ORR) of 57.7% (95% CI; 36.9-76.7). This included one patient (4 yo) with … (full text at CIViC) PMID 35395680 · Desai et al., 2022 · Open in CIViC	civic
〃	Pilocytic Astrocytoma	Predictive	C	Does Not Support Sensitivity Response	2	submitted	EID12604 In the STARTRK-NG Phase 1/2 trial of entrectinib in pediatric patients, with extracranial solid tumors or primary CNS tumors, aged <22 years with relapsed or refractory disease, tumors with fusions… (full text at CIViC) PMID 35395680 · Desai et al., 2022 · Open in CIViC	civic
〃	Low Grade Glioma	Predictive	C	Supports Sensitivity Response	1	accepted	EID11855 In a phase 1/2 trial of entrectinib in pediatric patients, tumors with fusions in NTRK, ROS1, or ALK had an overall response (ORR) of 57.7% (95% CI; 36.9-76.7). This included one patient (8 yo) with … (full text at CIViC) PMID 35395680 · Desai et al., 2022 · Open in CIViC	civic

ROS1 Fusion3
Crizotinib	Inflammatory Myofibroblastic Tumor	Predictive	C	Supports Sensitivity Response	3	accepted	EID1444 Case report of a pediatric patient with treatment-refactory inflammatory myofibroblastic tumor negative for ALK expression and rearrangement. Next generation sequencing of the patient revealed a TFG-R… (full text at CIViC) PMID 24875859 · Lovly et al., 2014 · Open in CIViC	civic
Entrectinib	Inflammatory Myofibroblastic Tumor	Predictive	C	Supports Sensitivity Response	2	accepted	EID11860 In a phase 1/2 trial of entrectinib in pediatric patients, tumors with fusions in NTRK, ROS1, or ALK had an overall response (ORR) of 57.7% (95% CI; 36.9-76.7). This included a patient with inflammat… (full text at CIViC) PMID 35395680 · Desai et al., 2022 · Open in CIViC	civic
〃	Inflammatory Myofibroblastic Tumor	Predictive	C	Supports Sensitivity Response	1	accepted	EID11862 In a phase 1/2 trial of entrectinib in pediatric patients, tumors with fusions in NTRK, ROS1, or ALK had an overall response (ORR) of 57.7% (95% CI; 36.9-76.7). This included a patient with myofibrob… (full text at CIViC) PMID 35395680 · Desai et al., 2022 · Open in CIViC	civic